Macquarie Begins Coverage of Danaher | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Noting the recent acquisition of Beckman Coulter and a strong operational model, investment firm Macquarie initiated coverage of Danaher with an Outperform rating and a $55 price target on its stock.

Analyst Jon Groberg gave revenue estimates for 2011 of $16.5 billion and adjusted EPS of $2.84.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.